Vizamyl™ (flutemetamol F 18 injection)
Vizamyl is a radiotracer indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
-Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline
-Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.
A single positive read region is sufficient to deem a Vizamyl scan as positive.
Comprehensive, clear scan results:
The following unique imaging features of Vizamyl can help add clarity to scan results:
- five defined read regions including the striatum-a region less affected by atrophy.1
-a full-color scale to support enhanced interpretation1,5
Consistent, reproducible scans:
Vizamyl uses the pons—a region unaffected by amyloid—as a consistent reference point for color scaling to support reproducible, confident reads across imagers, patients, and imaging centers.1
Precise quantification:
Quantification enables objective, reliableassessment of amyloid burden for informed patient management.3 Vizamyl visual scan interpretation, in conjunction with quantification, empowers clinicians to see clearly and make informed, timely decisions for Alzheimer’s patient
management.
References (-)
1. Vizamyl Prescribing Information. GE Healthcare; 2025.
2. Marinis M, Chatziioannou S, Kallergi M. Color as a high-value quantitative tool for PET/CT imaging. Information. 2025;16(5):352. doi:10.3390/info16050352.
3. Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508-28
